PTPN2 Elicits Cell Autonomous and Non–Cell Autonomous Effects on Antitumor Immunity in Triple-Negative Breast Cancer

Scientists explored the therapeutic potential of targeting PTPN2 in TNBC and T cells. PTPN2-deficiency in TNBC associated with T cell infiltrates and PD-L1 expression, whereas low PTPN2 associated with improved survival.